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The pituitary receptor for thyrotropin-releasing hormone (TRH) is a calcium-mobilizing G
protein-coupled receptor (GPCR) that signals through Gq/11, elevating calcium, and acti-
vating protein kinase C. TRH receptor signaling is quickly desensitized as a consequence
of receptor phosphorylation, arrestin binding, and internalization. Following activation,
TRH receptors are phosphorylated at multiple Ser/Thr residues in the cytoplasmic tail.
Phosphorylation catalyzed by GPCR kinase 2 (GRK2) takes place rapidly, reaching a max-
imum within seconds. Arrestins bind to two phosphorylated regions, but only arrestin
bound to the proximal region causes desensitization and internalization. Phosphorylation
at Thr365 is critical for these responses. TRH receptors internalize in clathrin-coated vesi-
cles with bound arrestin. Following endocytosis, vesicles containing phosphorylated TRH
receptors soon merge with rab5-positive vesicles. Over approximately 20 min these form
larger endosomes rich in rab4 and rab5, early sorting endosomes. After TRH is removed
from the medium, dephosphorylated receptors start to accumulate in rab4-positive, rab5-
negative recycling endosomes.The mechanisms responsible for sorting dephosphorylated
receptors to recycling endosomes are unknown. TRH receptors from internal pools help
repopulate the plasma membrane. Dephosphorylation ofTRH receptors begins whenTRH
is removed from the medium regardless of receptor localization, although dephosphoryla-
tion is fastest when the receptor is on the plasma membrane. Protein phosphatase 1 is
involved in dephosphorylation but the details of how the enzyme is targeted to the receptor
remain obscure. It is likely that future studies will identify biased ligands for theTRH recep-
tor, novel arrestin-dependent signaling pathways, mechanisms responsible for targeting
kinases and phosphatases to the receptor, and principles governing receptor trafficking.
Keywords: dephosphorylation, desensitization, internalization, phosphorylation, Rab, thyrotropin-releasing
hormone, trafficking,TRH receptor
INTRODUCTION
Thyrotropin-releasing hormone (TRH), a hypothalamic tripep-
tide, sits atop the hypothalamic/pituitary/thyroid axis, stimulating
release of thyrotropin from the anterior pituitary gland. TRH also
stimulates prolactin secretion (Figure 1). Initially characterized in
clonal rat pituitary cell lines, TRH binding sites were later iden-
tified in brain membranes (Hinkle and Tashjian, 1973; Burt and
Snyder, 1975). The link between TRH receptors and G proteins was
made at a time when heterotrimeric G proteins were thought to
transduce signals only from receptors coupled to adenylyl cyclase
(Hinkle and Kinsella, 1984; Hinkle and Phillips, 1984). It quickly
became clear that TRH receptors belong to the G protein-coupled
receptor (GPCR) superfamily. A single TRH receptor gene has
been found in humans and higher mammals and two genes encod-
ing homologous receptors, TRHR1 and TRHR2, in rodents (Sun
et al., 2003). TRHR1 predominates in the anterior pituitary gland
while both TRHR1 and TRHR2 are found in rodent CNS (O’Dowd
et al., 2000). Thyroid hormones exert powerful feedback inhibi-
tion over the TRH response system by inhibiting TRH synthesis
and processing in TRH neurons in the paraventricular region of
the hypothalamus and decreasing TRH receptors and responses
in the pituitary gland (Gershengorn, 1978; Perrone and Hinkle,
1978; Hinkle and Goh, 1982; Segerson et al., 1987; Fekete and
Lechan, 2007; Costa and Hollenberg, 2012). Prolonged hypothy-
roidism leads to a 40-fold increase in TRH receptor mRNA levels
in pituitary glands (Costa et al., 2012). In addition, pyroglu-
tamyl peptidase, a highly specific TRH-degrading ectoenzyme, is
dramatically increased in hyperthyroid animals (Schomburg and
Bauer, 1997; Marsili et al., 2011).
Genetic deletion of either the TRH peptide precursor or
TRHR1 results in central hypothyroidism and mild growth retar-
dation in mice, consistent with the established role of TRH in
thyroid physiology (Yamada et al., 1997; Rabeler et al., 2004; Zeng
et al., 2007). Interestingly, loss of the TRH receptor appears to
result in a more severe phenotype than loss of the TRH pep-
tide, possibly because the TRH receptor displays physiologically
significant constitutive activity. Mice lacking TRHR1 also exhibit
low prolactin and hyperglycemia, as well as increased anxiety and
depression. Some of these behavioral effects may be secondary to
hypothyroidism. Mice lacking TRHR2 display a subtle phenotype
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FIGURE 1 | Endocrine role of thyrotropin-releasing hormone. TRH,
acting via the type 1 TRH receptor, controls secretion from pituitary
thyrotrophs and lactotrophs. Thyroid hormones exert negative feedback
control.
consistent with depression and decreased anxiety (Sun et al., 2009).
In humans,absence of the TRH receptor causes low free T3 and free
T4 with thyroid stimulating hormone (TSH) levels inappropriately
low for the degree of hypothyroidism (Bonomi et al., 2009). Lack
of a TRH receptor does not result in infertility or failure to lactate.
This review focuses on aspects of TRH receptor signaling that
have been elucidated in either pituitary cell models expressing
endogenous receptors (pituitary tissue, primary cultures of pitu-
itary cells, cell lines derived from pituitary tumors) or generic cell
lines expressing transfected TRH receptors (HEK293, CHO, COS,
Hela). In rat anterior pituitary tissue, TRH receptor mRNA is
found not only in TSH-secreting cells but also in prolactin- and/or
growth hormone-secreting cells (Konaka et al., 1997). Although
the great majority of pituitary cells that bind rhodamine-labeled
TRH and respond to TRH with an increase in intracellular calcium
stain for prolactin or TSH-β, responses are occasionally observed
in unexpected cell types (Ashworth et al., 1995; Villalobos et al.,
1997; Yu et al., 1998). Signal transduction of endogenous TRH
receptors has not been characterized in neurons, where no suitable
model system has been identified. Even though there is only one
TRH receptor in higher mammals, that receptor may be regulated
quite differently in pituitary cells and neurons because of differ-
ent patterns of TRH stimulation and different sets of G protein
FIGURE 2 |Thyrotropin-releasing hormone signaling. TRH mobilizes
intracellular calcium and activates protein kinase C through a
well-characterized, Gq/11-dependent pathway. Phospholipase Cβ1, which is
activated primarily by Gα-GTP subunits, is the major effector in pituitary
cells. Intracellular calcium and protein kinase C initiate multiple responses
including activation of MAP kinase and regulation of ion channels.
subunits, effectors, receptors kinases, and phosphatases, arrestins,
and downstream targets.
As outlined in Figure 2, TRH receptors are textbook calcium-
mobilizing receptors: they are coupled to Gq and G11, which
activate phospholipase Cβ (PLCβ), hydrolysis of phosphatidyli-
nositol (4,5)bisphosphate, and release of the second messengers
inositol (1,4,5)triphosphate (IP3) and diacylglycerol (DG) that in
turn mobilize intracellular calcium and activate protein kinase C
(Drummond et al., 1984; Drummond, 1985; Gershengorn, 1989).
Two of the four forms of phospholipase Cβ (PLCβs 1 and 3) are
found in anterior pituitary tissue, and calcium responses to TRH
are intact in mice lacking PLCβ3 (Romoser et al., 2001). Thus
PLCβ1, which is stimulated by Gαq/11-GTP but not Gβγ, generates
second messengers in response to TRH. Maximal concentrations
of intracellular free calcium are attained at concentrations of TRH
at least an order of magnitude below the apparent K d of the
receptor and the EC50 for IP3 production. These initial events
are followed by complex changes that result in depolarization and
a sustained influx of extracellular calcium through voltage-gated
L-type calcium channels (Hinkle et al., 1996; Barros et al., 1997).
When TRH receptors are expressed in embryonic fibroblasts from
mice lacking Gαq and Gα11, TRH does not stimulate any increase
in intracellular calcium.
The TRH receptor is a rhodopsin family GPCR with typical
features including seven transmembrane domains, several extra-
cellular glycosylation sites, an essential disulfide bond between the
first and second extracellular loops, a fairly short third intracellular
loop, and a cytoplasmic tail. The receptor has a canonical (D/E)RY
at the cytoplasmic end of the third transmembrane segment, the
usual NPxxY at the cytoplasmic end of the seventh transmembrane
helix, and an intracellular eighth helix anchored by two palmitoy-
lated Cys residues in the carboxyl tail (Du et al., 2005). Except
for the most distal region, the cytoplasmic tail of the receptor is
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conserved among species. The C-terminal amino acids of numer-
ous GPCRs form classical PDZ ligands, sequences that can interact
with proteins bearing a PDZ domain; PDZ is an acronym for three
proteins containing the domain, PSD98, Dlg1, and zo-1 (Romero
et al., 2011). TRH receptors, however, do not contain sequences
predicted to interact with PDZ domains. Using a combination of
experimental data obtained with receptor mutants, multiple lig-
ands, and molecular modeling, Gershengorn and his colleagues
have developed a sequential model for receptor binding and acti-
vation in which the TRH tripeptide first interacts weakly with
extracellular loops and then moves deeper into the receptor and
contacts transmembrane domains to form a high affinity complex.
The conformational changes that occur upon receptor activation
involve movements in transmembrane helices 5 and 6 and the third
intracellular loop that result in G protein coupling (Gershengorn
and Osman, 1996).
DESENSITIZATION OF THE TRH RECEPTOR
Thyroid stimulating hormone displays a circadian pattern that is
attributed to rhythmic release of hypothalamic TRH. As a conse-
quence, desensitization and resensitization of the TRH signaling
pathway are likely to play central roles in regulating TRH actions
in vivo. TRH rapidly stimulates a large increase in IP3 mass, pro-
viding a proximal, easily quantified response. Measurements of
IP3 production have established that the TRH receptor undergoes
classical desensitization. Continuous application of TRH leads to
a transient burst of IP3 that peaks within seconds and falls within a
minute, though to levels that remain above baseline (Drummond
et al., 1984; Gershengorn and Osman, 1996; Yu and Hinkle, 1997,
1998). When cells are exposed to TRH intermittently, the size of the
IP3 response diminishes with successive stimulations. The extent
of desensitization depends on the method used to measure it and
the cell type under study (Falck-Pedersen et al., 1994). Decoupling
the receptor from G proteins contributes to the transient nature
of the IP3 elevation, which is more sustained in cells expressing
a TRH receptor that lacks most of the cytoplasmic tail and is
thereby spared from usual desensitization processes (Yu and Hin-
kle, 1998; Jones and Hinkle, 2005), as shown in Figure 3. Changes
further downstream in the signal pathway can also decrease TRH
responses by mechanisms including protein kinase C-mediated
inhibition of phospholipase Cβ and slow refilling of intracellu-
lar calcium stores (Yu and Hinkle, 1997). TRH receptors were
the first GPCRs shown to undergo what is now termed homol-
ogous downregulation (Hinkle and Tashjian, 1975; Gershengorn,
1978). Incubation with TRH decreases the number of TRH bind-
ing sites without changing receptor affinity in pituitary GH3 cells.
The molecular basis for downregulation is still not completely
understood.
Like many rhodopsin family GPCRs (Bulenger et al., 2005; Mil-
ligan, 2009; Lohse, 2010), TRH receptors form oligomers when
they are overexpressed in non-native cells (Kroeger et al., 2001;
Hanyaloglu et al., 2002; Zhu et al., 2002). Bioluminescence reso-
nance energy transfer (BRET), co-precipitation and biochemical
analyses have all been used to document TRH receptor homod-
imers, and the two rodent TRH receptors (TRHR1 and TRHR2)
form heterodimers (Hanyaloglu et al., 2002). TRH increases the
apparent fraction of receptors in dimers quantified by all of these
techniques, perhaps because TRH causes receptors to concen-
trate in clathrin-coated pits and endosomes. Truncated recep-
tors that do not recruit arrestin or internalize can form dimers
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FIGURE 3 | Importance of theTRH receptor carboxyl terminus.
Wildtype TRH receptors or receptors deleted at amino acid 334 were
incubated with TRH and IP3 mass was measured at intervals (graphs). To
visualize arrestin, receptors were expressed with GFP-labeled arrestin3. To
visualize receptors, cells were incubated with rhodamine-labeled TRH.
GFP-arrestin is recruited to full-length TRH receptors and co-internalizes
with them but it does not interact with truncated receptors, which do not
internalize.
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constitutively but not in response to TRH (Zhu et al., 2002). When
receptors are coerced to form oligomers by addition of a chem-
ical dimerizing agent, signaling is not altered but internalization
is accelerated and recycling blunted (Song and Hinkle, 2005). It
has been difficult to assess the physiological relevance of TRH
receptor dimers because no mutations that prevent oligomeriza-
tion have been identified and available methods are inadequate to
characterize endogenous receptors in pituitary cells. Recent stud-
ies (Whorton et al., 2007) have provided compelling evidence that
at least some rhodopsin family GPCRs can activate G proteins
as monomers, yet there are clear examples of receptors that form
heterodimers with unique pharmacology (Jordan and Devi, 1999).
One possibility is that that only one member of a GPCR pair signals
to a single G protein. The TRHR1/TRHR2 heterodimer interacts
with arrestins and internalizes in a different pattern from either
receptor alone (Pfleger et al., 2004), but the intriguing possibil-
ity that the TRH receptor forms heteromers with other GPCRs to
impart novel pharmacology has not been explored.
OVERVIEW OF GPCR RECEPTOR DESENSITIZATION
Most GPCRs become phosphorylated after they are activated, and
the TRH receptor is no exception. GPCR phosphorylation is cat-
alyzed by members of a family of Ser/Thr protein kinases, GPCR
kinases, or GRKs. There are seven GRKs, four of them widely
expressed (GRKs 1, 2, 5, and 6; Moore et al., 2007; Gurevich
et al., 2012). What sets the GRKs apart from other kinases is
their ability to discriminate between GPCRs in inactive versus acti-
vated conformations. They act preferentially on agonist-occupied
and constitutively active receptors and do not have strict require-
ments for the amino acid sequence surrounding phosphorylation
sites. There are important differences in how different GRKs
are recruited to the plasma membrane, however, and examples
of GPCRs that are phosphorylated at different sites by different
GRKs. GRKs exert a number of kinase-independent effects on
GPCR signaling and are known to phosphorylate substrates other
than receptors (Moore et al., 2007; Premont and Gainetdinov,
2007; Evron et al., 2012; Gurevich et al., 2012). GPCRs can also
be phosphorylated by kinases that become activated in response
to signaling such as cAMP-dependent protein kinase and pro-
tein kinase C. Phosphorylation carried out by such downstream
kinases can influence GPCR-G protein coupling, desensitization,
and trafficking.
Once activated and phosphorylated, most GPCRs bind to
arrestin, which interrupts the interaction between an activated
receptor and its cognate G protein and terminates signaling via
the G protein-mediated pathway. Arrestins 2 and 3 (also referred
to as β-arrestin1 and β-arrestin2) are ubiquitously expressed. Like
G proteins and GRKs, arrestins distinguish between inactive and
activated receptor conformations. Arrestins bind preferentially to
activated GPCRs; they also contain a positively charged pocket that
interacts strongly with negatively charged phosphates (Gurevich
and Gurevich, 2006; DeWire et al., 2007; Moore et al., 2007; Pre-
mont and Gainetdinov, 2007; DeFea, 2011; Shenoy and Lefkowitz,
2011). The arrestins therefore tend to bind with highest affin-
ity to receptors that are both activated and phosphorylated. When
arrestin engages receptor, a buried helical region in the arrestin car-
boxyl terminus undergoes a major translocation to expose binding
sites for AP2 and clathrin, targeting the arrestin-receptor complex
to coated pit regions of the membrane destined to pinch off into
endosomes in a dynamin-dependent process (Moore et al., 2007;
Shenoy and Lefkowitz, 2011).
Arrestin is a scaffolding protein capable of anchoring a wide
array of kinases, phosphatases, and other proteins to the arrestin-
GPCR complex (Xiao et al., 2007; DeFea, 2011). A rapidly expand-
ing body of literature shows that arrestin-GPCR complexes can
initiate alternate signaling pathways, notably those leading to
MAP kinase activation (Lefkowitz and Shenoy, 2005; Luttrell and
Gesty-Palmer, 2010; Reiter et al., 2012). The Lefkowitz group
has proposed that the phosphorylation pattern of a GPCR can
act as a barcode in which different phosphosites recruit differ-
ent arrestins to turn on different signal pathways (Liggett, 2011;
Nobles et al., 2011). This model is appealing because it adds
tremendous diversity to GPCR signaling, and it is supported by
evidence that arrestin2 and arrestin3 bind preferentially to dis-
tinct phophosites on several receptors (Ren et al., 2005). There are
also many examples of what are termed biased ligands that favor
particular pathways (Rajagopal et al., 2010; Reiter et al., 2012). For
example, biased ligands may preferentially activate G protein or
arrestin cascades, activate one arrestin signaling function but not
another (such as kinase activation and internalization), or act as
an agonist in one pathway and an antagonist in another. Biased
agonists and antagonists open new doors for the development of
therapeutically useful GPCR ligands.
G protein-coupled receptors have been broadly divided into
two groups based on their interactions with arrestins (Oakley et al.,
1999, 2000). Class A receptors bind arrestin 3 more strongly than
arrestin 2 or visual arrestin, internalize without associated arrestin,
and recycle rapidly. Examples include the well-characterized β2-
adrenergic receptor, the µ-opioid receptor and dopamine D1
receptor. Class B receptors bind well to both arrestin 2 and
arrestin 3, internalize with arrestin, and traffic to lysosomes where
they undergo intracellular degradation or slow recycling. Exam-
ples include the V2 vasopressin receptor, type 1a angiotensin II
receptor, and the TRH receptor.
PHOSPHORYLATION OF TRH RECEPTORS
Thyrotropin-releasing hormone receptors become phosphory-
lated rapidly once they are activated. Receptor phosphorylation
has been demonstrated by 32P incorporation, an upward mobil-
ity shift on gel electrophoresis, and reactivity with phosphosite-
specific antibodies (Hanyaloglu et al., 2001; Zhu et al., 2002; Jones
and Hinkle, 2005; Jones et al., 2007). All of these changes are
reversed by phosphatase treatment. Phosphorylation sites in the
TRH receptor have been partially mapped by characterizing 32P
incorporation and antibody reactivity of wildtype receptors and
receptors lacking various Ser and Thr residues in the cytoplasmic
tail. Jones et al. generated antisera against multiply phosphorylated
peptides from five different conserved regions of the TRH receptor
tail and validated their specificity (Jones and Hinkle, 2008). None
of the antibodies recognize TRH receptors from unstimulated
cells, but four of them react with receptors from TRH-treated cells.
Endogenous TRH receptors in pituitary cells are phosphorylated
strongly at residues between amino acids 355 and 365 and less effi-
ciently at two regions farther downstream. Current information
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about phosphosites in the TRH receptor C-terminus is presented
in Figure 4. As discussed below, phosphorylation of Thr365 is par-
ticularly important for arrestin recruitment, internalization, and
desensitization. There is no evidence for phosphorylation at Tyr
residues. The distal regions of the TRH receptor are more heavily
phosphorylated when the receptor is expressed in HEK293 or CHO
cells compared to native receptors. The finding of different site
usage in different settings suggests a need for caution when char-
actering phosphorylation of overexpressed epitope-tagged GPCRs
in heterologous cells, an approach that is normally required for
analysis by mass spectrometry.
Thyrotropin-releasing hormone receptor phosphorylation
does not appear to be hierarchical because the rates of phos-
phorylation are the same for different phosphosites. TRH does
not promote 32P incorporation into receptors truncated before
the palmitoylation site and TRH does not alter mobility of trun-
cated receptors, leading to the conclusion that either intracellular
loops are not phosphorylated in response to TRH or phospho-
rylation in the intracellular loops somehow requires the receptor
tail. Following TRH addition, nearly all receptors appear to be
phosphorylated based on the mobility shift and near quantitative
immunoprecipitation with phosphosite-specific antibodies (Jones
et al., 2007).
In pituitary cells, endogenous receptors on the plasma mem-
brane are not detectably phosphorylated in the basal state, but
they become strongly phosphorylated within 10 s of TRH addi-
tion and endocytosis of phospho-receptors is readily apparent by
10 min (Figure 5). Interestingly, when rat pituitary tissue from
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FIGURE 4 |Thyrotropin-releasing hormone receptor phosphorylation
sites. The circle outlines the portion of the rat TRH receptor depicted. Ser/Thr
residues are shown in pink or red in regions known to undergo
TRH-dependent phosphorylation. Phosphorylation at Thr365, in red, is
essential for desensitization and internalization, and phosphorylation at other
sites between amino acids 355 and 365 has been documented and shown to
contribute to these processes. TRH also stimulates phosphorylation at sites
from 371 to 391, although the exact phosphosites are not known.
Phosphorylation in this region is not essential for desensitization and
internalization, but it may be important for different, as yet unidentified
signaling functions. Phosphorylation in the non-conserved distal region has
not been examined.
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FIGURE 5 |Thyrotropin-releasing hormone-dependent phosphorylation of endogenousTRH receptors. Rat pituitary GH3 cells were stained with
affinity-purified antibody specifically recognizing phosphosites at amino acids 355–365 of the TRH receptor before and after TRH exposure.
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an untreated animal is examined, phosphorylated TRH receptor
is clearly visible. The intensity of the phospho-receptor signal
increases greatly minutes after animals are injected with TRH
and, as expected, the signal is seen cells that stain for TSH-β and
prolactin (Jones et al., 2007).
Thyrotropin-releasing hormone receptor phosphorylation is
exceedingly fast, with a half-time of 0.2 min (Jones et al., 2007;
Gehret and Hinkle, 2010). This rapid phosphorylation is unusual
among GPCRs and marks the TRH receptor as a superior sub-
strate. Rapid phosphorylation is not simply a consequence of the
sequence of the receptor tail. The transmembrane helices and
intracellular loops of the TRH receptor are likewise important for
rapid phosphorylation of the receptor tail even though they are
not phosphorylated themselves. A chimeric TRH receptor with
the β2-adrenergic receptor tail is phosphorylated at β2-adrenergic
receptor GRK sites with kinetics typical of the TRH receptor, not
the β2-adrenergic receptor (Gehret and Hinkle, 2010). The rate-
limiting step for TRH receptor phosphorylation may be recruit-
ment of GRKs to the activated receptor. In support of this idea,
dimerization of a mutant TRH receptor that cannot undergo
activation with a truncated TRH receptor that signals well but
cannot undergo phosphorylation results in phosphorylation of
the signaling-incompetent partner (Song et al., 2007). This is most
easily explained if the activatable receptor recruits a kinase that acts
on its partner in the receptor dimer. The predicted amphipathic
eighth helix between the canonical NPxxY at the end of the seventh
transmembrane domain and the palmitoylated Cys-X-Cys motif
is not phosphorylated but the positively charged residues in this
region are essential for phosphorylation at downstream sites and
subsequent internalization (Gehret et al., 2010).
Considerable evidence points toward GRK2 as the kinase
responsible for TRH receptor phosphorylation. Phosphorylation
is inhibited by dominant negative, kinase-dead forms of GRK2 and
by siRNAs targeting GRK2 (Jones and Hinkle, 2005; Jones et al.,
2007). The effects of siRNA knockdown are seen both in pitu-
itary cells and heterologous cells expressing transfected receptors.
In addition, paroxetine, which has recently been recognized as an
effective and relatively specific GRK2 inhibitor, delays phospho-
rylation of the TRH receptor (Thal et al., 2012). In keeping with
the rapid rate of TRH receptor phosphorylation, GRK2 translo-
cates to membrane fractions within 10 s of TRH addition (Jones
and Hinkle, 2005). All of these experiments implicate GRK2 in
TRH receptor phosphorylation, but because GRK2 knockdown
and inhibition do not block receptor phosphorylation completely
it seems likely that other GRKs are also able to phosphorylate the
receptor.
Inhibitor data suggest that casein kinase II, which is predicted
to phosphorylate Thr365 and two other downstream sites, may
contribute to receptor phosphorylation (Hanyaloglu et al., 2001).
Pharmacological activation of conventional protein kinase C iso-
forms leads to weak phosphorylation of some but not all sites
in the TRH receptor tail, but protein kinase C inhibitors do
not alter TRH-dependent phosphorylation (Jones et al., 2007).
Furthermore, TRH receptor phosphorylation and internalization
occur normally in cells lacking Gαq and Gα11, indicating that
calcium- and diacylglycerol-activated kinases are not essential
(Yu and Hinkle, 1999; Jones and Hinkle, 2005). Together these
results suggest little role for downstream kinases in TRH receptor
phosphorylation.
ARRESTIN INTERACTIONS WITH THE TRH RECEPTOR
Arrestin interactions with TRH receptors have been monitored by
a variety of approaches including translocation of GFP-arrestin
(Groarke et al., 1999, 2001; Oakley et al., 1999, 2000; Yu and
Hinkle, 1999; Smith et al., 2001; Hanyaloglu et al., 2002), co-
precipitation of arrestin and receptor (Jones et al., 2007), effect
of arrestin on agonist affinity (Jones and Hinkle, 2005, 2008), and
BRET (Kroeger et al., 2001; Hanyaloglu et al., 2002). GFP-arrestin
is diffusely localized in the cytoplasm of cells expressing TRH
receptors. When TRH is added, GFP-arrestin2 and GFP-arrestin3
move to the plasma membrane within a minute or two (see
Figure 3). The ability of TRH receptors to recruit arrestins 2 and
3 places it in the Group B category of GPCRs. Although arrestin
translocation is detectable with most GPCRs, arrestin movement
seen with the TRH receptor is exceptionally robust (Oakley et al.,
2000). GFP-arrestin translocation is not observed in cells express-
ing TRH receptors lacking palmitoylation sites or truncated before
the major phosphorylation sites (Vrecl et al., 1998; Yu and Hinkle,
1998; Hanyaloglu et al., 2001; Smith et al., 2001; Jones and Hinkle,
2005, 2008).
As shown in experiments depicted in Figure 6, GFP-arrestin
does translocate to receptors with Ala substitutions for the four
Ser and Thr residues between 355 and 365, proving that down-
stream phosphosites are sufficient to bind arrestin (Jones and
Hinkle, 2008). This is important because distal phosphosites are
not sufficient for desensitization and internalization, as discussed
below. Arrestin co-precipitates with activated TRH receptors even
if Ser/Thr residues in the 355–365 region are Ala-substituted, again
showing that arrestin interacts with at least two regions of the
receptor. BRET studies document a close interaction between the
type 1 TRH receptor and arrestins 2 and 3 that is lost if the receptor
is truncated before the palmitoylation sites (Pfleger et al., 2004).
Figure 7 summarizes current understanding about the importance
of different TRH receptor phosphorylation sites.
Because arrestins bind preferentially to activated GPCRs, theo-
retical considerations dictate that arrestin will increase the affinity
of a GPCR for agonists, a prediction borne out by experimental
evidence (Gurevich et al., 1997). Consistent with this, the apparent
affinity of the potent agonist [3H]MeTRH, measured at room tem-
perature or above in intact cells, is highly dependent on arrestin
levels (Jones and Hinkle, 2005, 2008). In arrestin2/3 knockout cells,
cotransfection with wildtype arrestin increases the apparent affin-
ity for [3H]MeTRH 14-fold. Arrestin increases the agonist affinity
of truncated and Ala-substituted receptors, supporting the con-
cept of multiple arrestin binding sites and raising the possibility
of phosphorylation-independent arrestin interactions.
ROLE OF ARRESTIN IN TRH RECEPTOR SIGNALING,
DESENSITIZATION AND INTERNALIZATION
Thyrotropin-releasing hormone receptors expressed in arrestin2/3
knockout cells generate strong IP3 responses to TRH. TRH-
stimulated IP3 levels are much lower in cells expressing arrestin2,
arrestin3, or both, proving that arrestin is important for desen-
sitization and that either arrestin is sufficient for this function.
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FIGURE 6 | Arrestin recruitment and arrestin-dependent desensitization.
Cells expressing the receptors shown were incubated with GFP-arrestin and
imaged before or after 3 min exposure to TRH. The right panels show
TRH-stimulated IP3 production in arrestin-null cells expressing receptor with
no arrestin (No Arr), wildtype arrestin 3 (wtArr), or R169E-Arr, which binds
activated GPCRs in a phosphorylation-independent fashion. TRH receptors
are: Wt, wildtype; 4Ala, Ala substituted for 4 Ser/Thr residues from amino
acids 355 through 365; and 4Ala-371Stop, 4Ala receptor truncated at amino
acid 370. Even though arrestin binds robustly to receptors lacking
phosphosites at amino acids 355–365, arrestin does not desensitize signaling.
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Phosphorylation
Arrestin binding
Desensitization
Internalization
T365 
TRH
+
+
+
+
+
+
 --
--
--
--
TRH
T365 
+
+
+
+
+
++++
TRH
+
--
--
--
--
++++
TRH
+
 +
+
--
--
++++
TRH
Role of Different Regions of TRH Receptor Carboxyl Terminus
FIGURE 7 | Importance of different phosphorylated regions of the
TRH receptor tail. Pink circles depict Ser/Thr residues in regions
known to be phosphorylated, with the critical Thr365 residue shown
in red. From left to right, TRH receptors are: wildtype, 4Ala
(Ala-substituted for the 4 Ser/Thr residues from amino acids 355
through 365), 371Stop (receptor truncated at amino acid 370),
C335Stop (receptor truncated before palmitoylation sites), and
receptor with Gln substitutions for 6 Arg/Lys residues between amino
acids 326 and 340. White circles depict Ser/Thr residues that are
present but weakly phosphorylated.
As expected, arrestins are not required for G protein-dependent
signaling. Arrestins do not desensitize IP3 responses if recep-
tors are missing phosphorylation sites between amino acids
355 and 365. Ala substitution of Thr365 severely impairs TRH
receptor desensitization and internalization. In contrast, recep-
tors truncated at amino acid 370 are still subject to arrestin-
mediated desensitization (Jones et al., 2007; Jones and Hinkle,
2008).
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A similar pattern emerges when internalization is examined.
Expression of dominant negative arrestin in normal cells or expres-
sion of receptors in arrestin-null cells severely restricts the rate
and extent of endocytosis (Hanyaloglu et al., 2002; Jones and
Hinkle, 2005, 2008). Endogenous arrestin levels control the desen-
sitization and internalization of heterologously expressed TRH
receptors; for example,HEK293 and even more so COS-7 cells have
lower concentrations of arrestin and correspondingly less desen-
sitization and internalization than pituitary cells (Falck-Pedersen
et al., 1994; Vrecl et al., 1998). Arrestin binding to phosphorylated
Thr365 and surrounding sites is absolutely required for inter-
nalization, but arrestin binding to phosphosites beyond amino
acid 370 is not necessary. The TRH receptor is one of several
examples where arrestin can bind to a GPCR without leading
to internalization (Krasel et al., 2008). Conversely, expression of
the R169E arrestin mutant, which binds activated GPCRs in a
phosphorylation-independent fashion, restores TRH-dependent
internalization to receptors lacking Thr365 and nearby phospho-
rylation sites (Hanyaloglu et al., 2001; Jones and Hinkle, 2008;
see Figure 6). Time- and temperature-dependent conversion of
receptor-bound radiolabeled peptide to an acid-resistant state has
often been taken as a measure of receptor endocytosis. It is worth
noting that this is not valid for receptor-bound [3H]MeTRH
(Jones and Hinkle, 2008). Acid resistance precedes internaliza-
tion and occurs at a reduced level with mutant receptors that do
not internalize at all and in cells where internalization is blocked.
Endocytosis can be documented readily by microscopy or by the
TRH-driven loss of surface binding sites for antibodies to an
N-terminal epitope tag on the receptor.
One question arising from these observations is whether inter-
nalization of TRH receptors contributes to early desensitization.
To address this question, TRH responses were quantified in set-
tings where receptor endocytosis was effectively blocked: in the
presence of hyperosmolar sucrose, in cells infected with vaccinia
virus encoding dominant negative dynamin, and in cells express-
ing receptors truncated just before the palmitoylation site (Yu and
Hinkle, 1998). Signaling was also measured in arrestin-null cells
transfected with a mutant arrestin that can bind to receptor but is
incapable of interacting with clathrin and AP2 (∆LIELD/F391A-
arrestin) and therefore incapable of promoting internalization
(Jones and Hinkle, 2005, 2008). Initial Gq/11-mediated responses
and subsequent desensitization of intact receptors were unaf-
fected by the lack of internalization, but the lack of a receptor tail
resulted in more persistent elevations in IP3 (Yu and Hinkle, 1998).
Together these results confirm the importance of arrestin for both
desensitization and internalization and prove that internalization
is not the cause of desensitization. In highly sensitive assays, per-
sistent IP1 production can be demonstrated for up to an hour
after TRH is washed out in HEK293 cells expressing TRH recep-
tors (Boutin et al., 2012). This sustained response does not depend
on internalization. The question of whether there are G protein-
independent signaling pathways and if so, whether they persist
following receptor endocytosis, has not been answered. For exam-
ple, TRH activates MAP kinase. A strong early activation depends
on protein kinase C-dependent raf phosphorylation but not on
internalization of the receptor itself, although it does require an
intact endocytic machinery (Ohmichi et al., 1994; Smith et al.,
2001). Additional work is needed to establish whether the weak
sustained activation of MAP kinase generated by TRH depends on
arrestin or continues following internalization in pituitary cells.
The known and possible additional roles of arrestin are shown
schematically in Figure 8.
MECHANISM OF TRH RECEPTOR INTERNALIZATION
Thyrotropin-releasing hormone promotes rapid and extensive
internalization of endogenous receptors in pituitary cells (Ash-
worth et al., 1995). Endocytosis of the activated TRH receptor
proceeds via a classical arrestin- and dynamin-dependent path-
way and is blocked by pharmacological inhibition of endocytosis
and by dominant negative dynamin (Drmota et al., 1998; Yu and
Hinkle, 1998). Gq/11-dependent signaling is not required, because
internalization occurs normally when TRH receptors are expressed
in fibroblasts from mice with genetic deletion of both Gαq and
Gα11, where there is no calcium response (Yu and Hinkle, 1999).
Regions of the cytoplasmic receptor tail important for internal-
ization correspond to regions where phosphorylation takes place
(Hanyaloglu et al., 2001, 2002; Jones et al., 2007). Endocytosis is
much slower although not entirely absent when the TRH receptor
is expressed in cells with either no arrestin or dominant negative
arrestins (Vrecl et al., 1998; Groarke et al., 2001; Smith et al., 2001;
Hanyaloglu et al., 2002; Jones and Hinkle, 2005). The mechanism
of the arrestin-independent component is unknown, but TRH
receptors appear to be excluded from caveolae (Rudajev et al.,
2005).
Ubiquitination is required for endocytosis of several GPCRs
(Hanyaloglu and von Zastrow, 2008; Hislop and von Zastrow,
2011) and a fraction of TRH receptors are ubiquitinated, but ubiq-
uitin is not added to receptors on the plasma membrane and ubiq-
uitination does not occur in response to TRH. Furthermore, recep-
tor endocytosis continues at the non-permissive temperature in
cells with a temperature-sensitive E1 ubiquitin-activating enzyme
(Cook et al., 2003). It is clear, then, that ubiquitination does not tag
TRH receptors for internalization, although ubiquitin-mediated
degradation serves an important quality control function during
TRH receptor biosynthesis.
TRH RECEPTOR TRAFFICKING
Trafficking of TRH receptors fused at the C-terminus to GFP has
been characterized by several groups (Drmota et al., 1998; Yu
and Hinkle, 1999; Scott et al., 2002). Shortly after TRH addition,
receptors cluster on the cell surface, and over the course of about
10 min they internalize in pre-assembled vesicles without trans-
ferrin receptors or Gαq. These earliest vesicles soon merge with
others containing transferrin receptors. Some Gαq is removed
from the plasma membrane following TRH receptor activation,
but this occurs quite slowly and internalized receptors and Gαq
are not colocalized (Drmota et al., 1999; Yu and Hinkle, 1999).
After 30 min or longer, GFP-labeled TRH receptors are found in
much larger vesicles deep inside the cell. TRH receptors internal-
ize together with arrestin (Groarke et al., 1999; Oakley et al., 2000;
Smith et al., 2001; Jones and Hinkle, 2008).
As described above, the TRH receptor follows a familiar pat-
tern of phosphorylation, arrestin binding, desensitization, and
endocytosis. Much less is understood about what happens next:
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FIGURE 8 | Arrestin effects onTRH receptor signaling. Arrestin binds to phosphorylated receptors, terminating receptor-G protein coupling, and initiating
receptor endocytosis. Arrestin is a scaffold for other signaling molecules and it is possible that the arrestin-TRH receptor complex controls as yet unidentified
pathways.
how is the TRH receptor (and other GPCRs) dephosphorylated,
sorted and trafficked back to the plasma membrane or targeted
for degradation? In a study that capitalized on the availability
of antibodies specific for phosphorylated TRH receptors, traf-
ficking of phosphorylated, and dephosphorylated TRH receptors
was monitored during internalization and recycling. Endosomal
compartments were identified with GFP-labeled Rab proteins, and
movements of fluorescently labeled arrestin were followed simul-
taneously (Jones and Hinkle, 2009). Cell surface receptors were
selectively labeled with antibody against an HA tag on the extra-
cellular N-terminus of the rat TRH receptor (“antibody feeding”)
and tracked over time following addition or withdrawal of TRH.
Rab5 marks an early endosomal population, and TRH recep-
tors appeared in Rab5-positive vesicles within a few minutes of
TRH stimulation. Receptors in these vesicles were almost entirely
phosphorylated and associated with arrestin. Over the course of
20 min, receptors moved to vesicles that were both rab4- and rab5-
positive, the early sorting endosomes. Both phosphorylated and
non-phosphorylated receptors were seen in this pool. Internalized
receptors subsequently trafficked to a population of vesicles that
were rab4-positive but rab5-negative, typical of rapidly recycling
endosomes. These recycling vesicles were enriched in dephospho-
rylated receptors, i.e., receptors that began the experiment on the
plasma membrane but were no longer phosphorylated. They were
essentially devoid of phosphorylated receptors.
This result raised the question: were receptors able to move into
this rab4-positive, rab5-negative “recycling” vesicle population
because they were dephosphorylated, or were receptors quickly
dephosphorylated once they reached these vesicles? This question
was addressed by interrupting normal trafficking with domi-
nant negative rabs. Dominant negative rab5 completely blocked
movement of the receptor out of very early endosomes, yet it did
not change the rate of receptor dephosphorylation. If dephospho-
rylation occurred preferentially in a later endosomal population,
dominant negative rab5 would have delayed phosphatase action.
These results lead to the conclusion that dephosphorylation takes
place in sorting endosomes and permits trafficking of the TRH
receptor into recycling vesicles.
A small subset of phosphorylated TRH receptors eventually
appear in Rab11 vesicles, traditionally viewed as a late recycling
compartment, suggesting that the long recycling pathway is taken
by some receptors. Rab7 vesicles, which are associated with lyso-
somes, contained very little TRH receptor. It seems plausible that
a fraction of intracellular receptor is degraded with each round
of internalization, possibly contributing to the phenomenon of
downregulation, but this remains speculative. The trafficking of
internalized TRH receptors is summarized in Figure 9.
REPOPULATING THE PLASMAMEMBRANE: RECYCLING AND
RECRUITMENT
When cells are incubated with TRH to drive internalization and the
hormone is removed, receptors reappear at the plasma membrane
with a half-time of 20–30 min based on the amount of radioactive
TRH able to bind, the amount of epitope-tagged receptor on the
membrane determined by FACS or ELISA, or the amount of GFP-
labeled receptor at the surface. These results are consistent with
receptor recycling, but the story has recently grown more compli-
cated with the discovery that although the total receptor number at
the plasma membrane is restored quite quickly, this is largely due
to recruitment of new receptors (Cook and Hinkle, 2004; Jones
and Hinkle, 2009). An early piece of evidence appeared when
the TRH receptor was fused to a derivative of DS-Red dubbed
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FIGURE 9 | Intracellular trafficking ofTRH receptors. TRH activation is
rapidly followed by receptor phosphorylation, arrestin binding, and
recruitment of the arrestin-phospho-receptor complex to clathrin-coated
pits that pinch off in a dynamin-dependent process to form
clathrin-coated vesicles (CCVs). Vesicles containing phospho-receptor
soon merge with rab5-positive vesicles where they colocalize with
transferrin receptors. These vesicles gradually merge with others to form
larger endosomes rich in rab4 and rab5, early sorting endosomes. After
TRH is removed from the medium, but not before, dephosphorylated
receptors start to become detectable in rab4-positive but rab5-negative
recycling endosomes. Dephosphorylated receptors then recycle to the
plasma membrane. Phosphorylated receptor is rarely seen in these fast
recycling vesicles. After long incubations with TRH, small amounts of
phospho-receptor are detected in rab11 vesicles, considered to be a slow
recycling pool. Protein phosphatase 1 (PP1) acts on theTRH receptor, but
it is not known how the removal of extracellular TRH triggers receptor
dephosphorylation. The mechanism that permits dephosphorylated
receptors to move to recycling endosomes, or alternatively the
mechanism that prevents phosphorylated receptors from exiting early
sorting vesicles, are also not clear.
“Timer.” The unique feature of the Timer protein is that it changes
color from red to green with a half-time of 10 h. When TRH was
added to drive internalization and then removed to allow recy-
cling, receptors that moved to the plasma membrane were much
redder (younger) than those that had been internalized (Cook and
Hinkle, 2004). A second approach was an antibody feeding study
which showed that intracellular receptors were recruited to the
membrane before the internalized receptors had recycled (Jones
and Hinkle, 2009). To avoid problems inherent in antibody feed-
ing experiments, TRH receptors were fused at the N-terminus to
a 15 amino acid tag that serves as a biotin ligase acceptor. Plasma
membrane receptors were selectively labeled with biotin by adding
purified bacterial biotin ligase, biotin, and ATP to the medium.
TRH receptors on the plasma membrane were essentially the
only proteins biotinylated, and biotin-labeled TRH receptor was
visualized with fluorescent streptavidin. Again, after TRH-driven
endocytosis and several hours of recovery, the surface receptor
pool was repopulated initially with recruited rather than recy-
cled (biotin-labeled) receptors (Jones and Hinkle, 2009). Finally,
cells were labeled with [3H]TRH (not the higher affinity, slower
dissociating [3H]MeTRH), which internalized with the receptor.
When [3H]TRH was removed, plasma membrane receptor lev-
els were restored at a time when most [3H]TRH still remained
inside the cell. In each of these approaches, most internalized
receptors eventually returned to the plasma membrane, but only
after an hour or more (Jones and Hinkle, 2009). These results pro-
vide another question for future study: How are receptors in an
intracellular pool prompted to move to the plasma membrane?
GPCR DEPHOSPHORYLATION
Once a GPCR is activated, phosphorylated, and bound to arrestin,
return to its resting state requires dissociation or degradation of the
agonist, dissociation of arrestin and dephosphorylation. With rare
exceptions, the phosphatases responsible for GPCR dephospho-
rylation have not been fully characterized. There are many more
GPCRs than Ser/Thr phosphatases, necessitating involvement of
enzymes with broad substrate specificity. In mammalian cells, the
majority of proteins phosphorylated on Ser and Thr residues are
dephosphorylated by members of two ubiquitous enzyme families,
protein phosphatase 1 (PP1), and protein phosphatase 2A (PP2A;
Barford et al., 1998). These protein phosphatases are multisubunit
enzymes that achieve specificity by interacting with a wide array of
scaffolding and targeting subunits. The catalytic subunits of PP1s
can bind directly to substrates through a number of conserved
motifs or localize through targeting subunits. Over 150 proteins
have been shown to interact with PP1 (Bollen et al., 2010). PP2As
are heterotrimers composed of a catalytic subunit, a scaffolding or
structural subunit, and a targeting subunit. On the basis of high
Frontiers in Neuroscience | Neuroendocrine Science December 2012 | Volume 6 | Article 180 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hinkle et al. TRH receptor trafficking
sensitivity to inhibitors, the PP2A family of phosphatases has been
implicated in the dephosphorylation of numerous GPCRs, and
PP1, calcineurin (PP2B), and PP2C for others (Croci et al., 2003;
Flajolet et al., 2003; Mao et al., 2005).
Pitcher et al. (1995) reported that the β2-adrenergic receptor
was dephosphorylated by an endosomal phosphatase in the PP2A
family following internalization . This model predicted an essential
role for receptor endocytosis: a GPCR had to cycle through endo-
somal compartments to be dephosphorylated and resensitized.
Subsequent work has uncovered many variants on this theme.
Many GPCRs can be dephosphorylated while localized on the
cell surface. Dephosphorylation of PKA and GRK sites on the
β2-adrenergic receptor can take place on the plasma membrane
(Iyer et al., 2006). Some sites on the somatostatin 2A receptor are
not dephosphorylated until the receptor has internalized, while
others can be dephosphorylated regardless of receptor location;
different enzymes appear to be involved (Ghosh and Schonbrunn,
2011). Receptors for several peptide hormones cannot recycle
until the peptide is degraded in acidified endosomes in a reaction
catalyzed by ectopeptidases that cointernalize with the peptide-
receptor complex (Roosterman et al., 2008; Cattaruzza et al., 2009).
Although the TRH-degrading enzyme is an ectoenzyme present
in pituitary tissue, there is no evidence that it plays a role in TRH
receptor cycling.
TRH RECEPTOR DEPHOSPHORYLATION
When TRH is removed from the medium or an inverse agonist
such as chlordiazepoxide is added, receptor dephosphorylation
rapidly ensues (Jones and Hinkle, 2005; Jones et al., 2007; Gehret
and Hinkle, 2010, 2012). Once TRH dissociates, receptors return
to an inactive conformation, arrestin affinity declines, and arrestin
dissociation provides freer access of phosphatases. A number of
studies have sought to identify factors controlling the rate of
receptor dephosphorylation. The amino acid sequence surround-
ing the phosphosite does not seem to be a major factor because
the rates of TRH receptor dephosphorylation are the same at dif-
ferent phosphosites (Jones et al., 2007). When the β2-adrenergic
receptor tail was spliced onto the TRH receptor, the chimeric
receptor underwent TRH-dependent phosphorylation at sites that
are phosphorylated by GRKs in the β2-adrenergic receptor. The
dephosphorylation kinetics of the chimera resembled those of the
natural TRH receptor (Gehret and Hinkle, 2010). On the other
hand, the location of the TRH receptors is important (Jones et al.,
2007; Gehret and Hinkle, 2010). Dephosphorylation occurs more
rapidly when receptors are on the plasma membrane than when
receptors have undergone endocytosis. In pituitary cells, endoge-
nous receptors are dephosphorylated with a half-time of about
45 s if TRH exposure lasts only a minute (sufficient for complete
phosphorylation but not for internalization) but is 3 min if TRH
exposure continues for 30 min (when receptors have undergone
internalization; Jones et al., 2007). A similar situation holds in
heterologous model systems, although dephosphorylation is not
nearly as fast.
These data raise an important question: how does removing
TRH from the outside of the cell trigger dephosphorylation of
receptors in endosomes deep in the cytoplasm? The simplest idea
is that some receptors are always at the plasma membrane and as
long as TRH is present, they are signaling and somehow main-
taining receptor phosphorylation. Removing extracellular TRH
terminates signaling and leads to dephosphorylation. If this model
is valid, however, the responsible signaling system cannot be tra-
ditional Gq/11-mediated activation of PLCβ, because dephospho-
rylation of internalized receptors is not altered by treatment with
an intracellular calcium chelator and protein kinase C inhibitor
(Jones et al., 2007).
Recently, the problem of identifying the TRH receptor phos-
phatase was tackled using an unbiased screen with an siRNA
library directed against phosphatase subunits (Gehret and Hinkle,
2012). While this approach had the potential to identify a targeting
or scaffolding subunit, only the catalytic subunit of PP1α came up
as a bone fide hit in the screen. The results of the screen, which
was performed in HEK293 cells, concur with inhibitor effects
on dephosphorylation of endogenous TRH receptors in pituitary
cells. Dephosphorylation of TRH receptors is powerfully inhib-
ited by calyculin A, which acts on the catalytic subunits of PP1 and
PP2A, but insensitive to fostriecin, a highly selective inhibitor of
PP2A. Many details, such as the mechanism that targets PP1α to
the receptor, remain to be elucidated. The discovery of a specific
phosphatase subunit acting on the TRH receptor provides a start-
ing point for dissecting an important aspect of the resensitization
process.
FUTURE DIRECTIONS
The TRH receptor has been viewed as a prototypical “calcium-
mobilizing” GPCR and the mechanisms of TRH signaling have
been the subject of intense investigation for decades. More recently,
attention has also been focused on events that turn signaling
off. In every instance, the pathways involved have turned out
to be more complex than anticipated. This review has sought to
review recent work and highlight some of the unknowns pertain-
ing to TRH receptor signaling, desensitization, and trafficking.
Once activated by hormone, the TRH receptor is phosphory-
lated in multiple regions; arrestins bind at different phosphosites
with different consequences. It seems likely that the TRH recep-
tor signals via its diverse arrestin interactions in ways that are
not yet recognized. The trafficking studies described here show
that dephosphorylation must take place before internalized TRH
receptors can recycle, yet the nature of the interaction between
receptor and phosphatase remains elusive. The recent identifi-
cation of the protein phosphatase involved opens the door for
future studies seeking to describe phosphatase targeting mecha-
nisms. The principles governing receptor trafficking are not well
understood, and it is unclear how phosphorylated and desphos-
phorylated receptors are sorted in endosomes. High throughput
screening techniques have aided in the discovery of biased ligands
with the capacity to control specific aspects of receptor function,
and it is to be hoped that designer ligands for TRH receptors will
provide new tools for research or even novel drugs for treating
thyroid disease. Finally, long awaited information on the structure
of the TRH receptor can be expected in the not too distant future.
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